Clinical evaluation of a live orally administered adenovirus 4 vaccine was conducted at the Naval Training Center, Great Lakes, III. In a double-blind epidemiologic investigation the effectiveness of this newer vaccine was compared to that of two other inactivated adenovirus 4 vaccines and appropriate placebos in a population of 2,307 recruits. By detailed clinical examination of all participants requiring hospitalization (644 admissions), syndrome-specific incidences of acute undifferentiated respiratory disease (ARD) and of other respiratory syndromes were derived. Each of the adenovirus vaccines effected a similar 50% to 60% relative reduction of ARD, as well as symptomspecific decreases in the incidence of clinical manifestations of ARD. No evidence of a clinical toxic effect of the live adenovirus vaccine administered orally was detected.
Griffin JP, Greenberg BH. Live and Inactivated Adenovirus VaccinesClinical Evaluation of Efficacy in Prevention of Acute Respiratory Disease. Arch Intern Med. 1970;125(6):981-986. doi:10.1001/archinte.1970.00310060059005